<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65317">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255552</url>
  </required_header>
  <id_info>
    <org_study_id>4658-301</org_study_id>
    <nct_id>NCT02255552</nct_id>
  </id_info>
  <brief_title>Confirmatory Study of Eteplirsen in DMD Patients</brief_title>
  <acronym>PROMOVI</acronym>
  <official_title>An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to provide confirmatory evidence of efficacy of
      eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to
      skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the
      long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to
      exceed 48 weeks).

      Sites are currently being initiated into the study. Initiation of approximately 39 planned
      sites in the United States is expected to be completed by June 2016. The initiated sites can
      be found in the &quot;Contacts and Locations&quot; section of this posting in addition to a listing of
      the city and states of sites the investigators are working to initiate. This information
      will be updated on a rolling basis as additional sites are initiated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, 96-week study to evaluate the efficacy and safety of
      eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with
      genetic deletions amenable to exon 51 skipping (treated group), with a concurrent control
      arm of DMD patients not amenable to exon 51 skipping (untreated group). Following primary
      efficacy endpoints at week 48, dosing will continue to week 96 to evaluate the long term
      effects of eteplirsen.

      Patients in the treated group will receive once weekly intravenous (IV) infusions of 30
      mg/kg Eteplirsen. Patients in the untreated group will not receive treatment.

      Clinical efficacy will be assessed at regularly scheduled study visits, including functional
      tests such as the six minute walk test. Patients in the treated group will undergo a muscle
      biopsy at Baseline and a second muscle biopsy over the course of the study. Patients in the
      untreated group will not undergo muscle biopsy.

      Safety, including adverse event monitoring and routine laboratory assessments, will be
      continuously monitored for all patients.

      The sponsor is working to initiate approximately 39 sites across the United States. Sites
      will vary in the following functions:

        1. Local Site (N=39) - Enrolls patients and is the primary contact point for their
           patients. Sites will perform all protocol activities (including dosing and laboratory
           assessments), except for functional assessments and biopsies.

        2. Hub Site (N=14) - Performs functional (physical) assessments at specified times per
           protocol.

        3. Surgical Site (N=2) - Performs muscle biopsies for the Treated group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-Minute Walk Test (6MWT) distance from baseline</measure>
    <time_frame>Baseline, Weeks 12, 24, 36, 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of dystrophin-positive fibers</measure>
    <time_frame>Baseline, Weeks 24, 48, 72, 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum inspiratory/expiratory pressure percent predicted (MIP/MEP % predicted)</measure>
    <time_frame>Baseline, Weeks 12, 24, 36, 48</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluate the long-term effects of eteplirsen up to 96 weeks</measure>
    <time_frame>Week 1-96</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Duchenne Muscular Dystrophy (DMD)</condition>
  <arm_group>
    <arm_group_label>Treated Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Approximately 80 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>eteplirsen</intervention_name>
    <description>Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).</description>
    <arm_group_label>Treated Group</arm_group_label>
    <other_name>AVI-4658</other_name>
    <other_name>EXONDYS 51</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 7-16 years old

          -  Diagnosed with DMD, genotypically confirmed

          -  Stable dose of corticosteroids for at least 24 weeks

          -  Have intact right and left alternative upper muscle groups

          -  Mean 6MWT greater than 300m (primary analysis on 300 to 450 meters)

          -  Stable pulmonary and cardiac function: predicted FVC equal to or greater than 50% and
             LVEF of greater than 50%

        Exclusion Criteria:

          -  Previous treatment with drisapersen or any other RNA antisense agent or any gene
             therapy within the last 6 months

          -  Participation in any other DMD interventional clinical study within 12 weeks

          -  Major surgery within 3 months

          -  Presence of other clinically significant illness

          -  Major change in the physical therapy regime within 3 months

        Other inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petra Duda, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward M. Kaye, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kara Boniface</last_name>
    <email>trialinfo@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Osgood</last_name>
      <phone>480-314-1007</phone>
      <email>kosgood@nrcaz.com</email>
    </contact>
    <investigator>
      <last_name>Kumaraswamy Sivakumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Vargas</last_name>
      <phone>310-825-3264</phone>
      <email>AndresVargas@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Aguilar</last_name>
      <email>candace.aguilar@ucdmc.ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Erica Goude</last_name>
      <phone>916-734-0968</phone>
      <email>erica.goude@ucdmc.ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital, U.C. San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlene Smith</last_name>
      <phone>858-966-6246</phone>
      <email>awsmith@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Carla Grosmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Mclaughlin</last_name>
      <phone>650-206-3178</phone>
      <email>cjmclaug@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Johnson</last_name>
      <phone>720-777-3293</phone>
      <email>Hannah.Johnson@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Julie Parsons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendriana Nielsen</last_name>
      <phone>860-837-5881</phone>
      <email>HNielsen@connecticutchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Gyula Acsadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tekolla Belaineh</last_name>
      <phone>202-476-2635</phone>
      <email>TBelaine@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Mathula Thangarajh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Florida, Powell Gene Therapy Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Salabarria</last_name>
      <phone>352-273-8218</phone>
      <email>ssalabarria@ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Barry J Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NW FL Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shezsay Lancelin</last_name>
      <phone>850-221-5116</phone>
      <email>shae.lancelin@cneurology.com</email>
    </contact>
    <investigator>
      <last_name>Ben Renfroe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospitals and Clinics</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Quesada</last_name>
      <phone>305-243-7424</phone>
      <email>mquesada2@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Khema Ram Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Berry</last_name>
      <phone>407-650-7523</phone>
      <email>Debbie.Berry@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Richard Finkel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saadia Khizer</last_name>
      <phone>404-393-3205</phone>
      <email>Saadia.Khizer@choa.org</email>
    </contact>
    <investigator>
      <last_name>Han C Phan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Schulte</last_name>
      <phone>312-227-3813</phone>
      <email>dschulte@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Nancy Kuntz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madalyn Rasor</last_name>
      <phone>319-384-9619</phone>
      <email>madalyn-rasor@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiley Sims</last_name>
      <phone>913-945-9922</phone>
      <email>ksims2@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Barohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Yep</last_name>
      <phone>443-923-7318</phone>
      <email>Yep@kennedykrieger.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Wagner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karyn Barrett</last_name>
      <phone>617-643-4662</phone>
      <email>kebarrett@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Fawn Leigh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Harrington</last_name>
      <phone>857-218-4677</phone>
      <email>Timothy.Harrington@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Basil Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ae (Mae) Nordin</last_name>
      <phone>313-966-0488</phone>
      <email>mnordin@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Huiyuan Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna Rugierro</last_name>
      <phone>612-625-4882</phone>
      <email>ruggi020@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krystal Reese</last_name>
      <phone>314-362-1146</phone>
      <email>reesek@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Anne M Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Ortiz Miller</last_name>
      <phone>212-305-2461</phone>
      <email>co2391@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Darryl De Vivo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Clinical Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Smith</last_name>
      <phone>585-275-4339</phone>
      <email>Patty_Smith@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Emma Ciafaloni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Childrens Hospital, Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Little</last_name>
      <phone>704-446-3491</phone>
      <email>anja.little@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Binalsheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Collins</last_name>
      <phone>513-636-5517</phone>
      <email>andrea.collins@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Cuixia Tian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kandice Roush, RN</last_name>
      <phone>614-722-2558</phone>
      <email>Kandice.Roush@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Jerry R Mendell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Rother</last_name>
      <phone>971-544-3377</phone>
      <email>RWR@shcc.org</email>
    </contact>
    <investigator>
      <last_name>Erika Finanger, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Runk</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>287177</phone_ext>
      <email>hrunk@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Wicklund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Bergman</last_name>
      <phone>267-425-2111</phone>
      <email>BERGMAN@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Gihan Tennekoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer M Monahan</last_name>
      <phone>412-692-5176</phone>
      <email>jennifer.monahan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hoda Z Abdel-Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center/MDA Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Davis</last_name>
      <phone>615-322-8957</phone>
      <email>diana.davis@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>William Burnette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly Lawrence</last_name>
      <phone>214-456-2463</phone>
      <email>holly.lawrence@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristy Riddle</last_name>
      <phone>214-456-9501</phone>
      <email>Kristy.Riddle@childrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Susan T Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariam Pontifes</last_name>
      <phone>832-822-1268</phone>
      <email>mepontif@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Tim Lotze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bria Jensen</last_name>
      <phone>801-585-9399</phone>
      <email>briaj@genetics.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Butterfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont College of Medicine</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Lucy</last_name>
      <phone>802-656-4582</phone>
      <email>Shannon.lucy@med.uvm.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Hehir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Christensen</last_name>
      <phone>206-884-2756</phone>
      <email>ana.christensen@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Susan Apkon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 27, 2016</lastchanged_date>
  <firstreceived_date>September 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
